Published in Wien Med Wochenschr on April 30, 1986
Primary gastric B-cell lymphoma: results of a prospective multicenter study. The German-Austrian Gastrointestinal Lymphoma Study Group. Gastroenterology (2000) 2.65
Complete remission of metastasised clear cell sarcoma of tendons and aponeuroses. Eur J Cancer (1991) 1.44
A clinical phase II study with sorafenib in patients with progressive hormone-refractory prostate cancer: a study of the CESAR Central European Society for Anticancer Drug Research-EWIV. Br J Cancer (2007) 1.33
An open-label, randomized phase II study of adecatumumab, a fully human anti-EpCAM antibody, as monotherapy in patients with metastatic breast cancer. Ann Oncol (2009) 1.12
Synergistic activation of interleukin-8 gene transcription by all-trans-retinoic acid and tumor necrosis factor-alpha involves the transcription factor NF-kappaB. J Biol Chem (1996) 1.11
Predictive impact of 2-18fluoro-2-deoxy-D-glucose positron emission tomography for residual postchemotherapy masses in patients with bulky seminoma. J Clin Oncol (2001) 1.09
Prognostic value of the rupture of the capsule in stage I epithelial ovarian carcinoma. Gynecol Oncol (1989) 1.03
Cetuximab in combination with weekly 5-fluorouracil/folinic acid and oxaliplatin (FUFOX) in untreated patients with advanced colorectal cancer: a phase Ib/II study of the AIO GI Group. Ann Oncol (2008) 1.02
Monoclonal rat antibodies directed against Toxoplasma gondii suitable for studying tachyzoite-bradyzoite interconversion in vivo. Clin Diagn Lab Immunol (1995) 1.00
A randomised phase II study of two different schedules of pegylated liposomal doxorubicin in metastatic breast cancer (EORTC-10993). Eur J Cancer (2006) 0.96
Retinoic acid induced death of ovarian carcinoma cells correlates with c-myc stimulation. Int J Cancer (1995) 0.96
2-¹⁸fluoro-deoxy-D-glucose positron emission tomography (FDG-PET) for postchemotherapy seminoma residual lesions: a retrospective validation of the SEMPET trial. Ann Oncol (2011) 0.95
Diffuse large B-cell lymphomas with plasmablastic/plasmacytoid features are associated with TP53 deletions and poor clinical outcome. Leukemia (2004) 0.95
Early results from a phase I study on orally administered tris(8-quinolinolato)gallium(III) (FFC11, KP46) in patients with solid tumors--a CESAR study (Central European Society for Anticancer Drug Research--EWIV). Int J Clin Pharmacol Ther (2005) 0.94
Simultaneous and sequential determinations of steroid hormone receptors in human breast cancer. Influence of intervening therapy. Ann Surg (1985) 0.94
Prognostic significance of liver metastases as first site of generalisation in patients with breast cancer--a retrospective analysis. Acta Med Austriaca (2001) 0.93
Docetaxel extravasation. Support Care Cancer (2001) 0.91
Bidirectional interactions between the estrogen receptor and the cerbB-2 signaling pathways: heregulin inhibits estrogenic effects in breast cancer cells. Int J Cancer (1995) 0.91
Phase II study of E7070 in patients with metastatic melanoma. Ann Oncol (2005) 0.90
European Organization for Research and Treatment of Cancer (EORTC) open label phase II study on glufosfamide administered as a 60-minute infusion every 3 weeks in recurrent glioblastoma multiforme. Ann Oncol (2003) 0.89
[Clinical significance of the tumor marker CA-125 for the preoperative diagnosis and postoperative management of patients with malignant ovarian cancers]. Geburtshilfe Frauenheilkd (1985) 0.88
The clinical course of lung metastases from breast cancer. Klin Wochenschr (1988) 0.86
Regulation of developmental differentiation in the protozoan parasite Toxoplasma gondii. J Eukaryot Microbiol (1996) 0.86
The effects of dimethyl sulfoxide and retinoic acid on the cell growth and the phenotype of ovarian cancer cells. J Cell Sci (1991) 0.86
Toxicity and response to high-dose ifosfamide + mesna as salvage therapy for advanced breast cancer. J Cancer Res Clin Oncol (1988) 0.86
Comparative analysis of the effects of dimethyl sulfoxide and retinoic acid on the antigenic pattern of human ovarian adenocarcinoma cells. J Cell Sci (1992) 0.84
Sodium butyrate inhibits c-myc splicing and interferes with signal transduction in ovarian carcinoma cells. Carcinogenesis (1995) 0.84
Phase II study of amonafide in advanced breast cancer. Breast Cancer Res Treat (1991) 0.83
Vinorelbine-induced neurotoxicity in patients with advanced breast cancer pretreated with paclitaxel--a phase II study. Cancer Chemother Pharmacol (1996) 0.83
Macrophage colony-stimulating factor is expressed by an ovarian carcinoma subline and stimulates the c-myc proto-oncogene. Br J Cancer (1995) 0.83
Relationship of myc protein expression to the phenotype and to the growth potential of HOC-7 ovarian cancer cells. Br J Cancer (1992) 0.83
Phase II study of XR5000 (DACA) administered as a 120-h infusion in patients with recurrent glioblastoma multiforme. Ann Oncol (2002) 0.83
The value of second-look operation in patients with advanced epithelial ovarian carcinoma. Arch Gynecol Obstet (1989) 0.83
The human tumour cloning assay in the management of breast cancer patients. Br J Cancer (1985) 0.82
Retinoic acid receptors in retinoid responsive ovarian cancer cell lines detected by polymerase chain reaction following reverse transcription. Br J Cancer (1993) 0.82
Carcinoembryonic antigen (CEA) plasma level determination in the management of gastric cancer patients. Cancer Detect Prev (1985) 0.82
Separation of clonogenic and differentiated cell phenotypes of ovarian cancer cells (HOC-7) by discontinuous density gradient centrifugation. Cancer Lett (1991) 0.81
Mucin-like cancer-associated antigen (MCA) compared with CA 15-3 in advanced breast cancer. Klin Wochenschr (1989) 0.81
The differential effects of N,N-dimethylformamide and transforming growth factor-beta 1 on a human ovarian cancer cell line (HOC-7). J Cell Physiol (1992) 0.81
Phase II study of OSI-211 (liposomal lurtotecan) in patients with metastatic or loco-regional recurrent squamous cell carcinoma of the head and neck. An EORTC New Drug Development Group study. Eur J Cancer (2004) 0.80
Different propensity for spontaneous differentiation of cell clones isolated from the human ovarian surface epithelial cell line HOC-7. Differentiation (1993) 0.80
Evaluation of plasma 5-fluorouracil nucleoside levels in patients with metastatic breast cancer: relationships with toxicities. Cancer Chemother Pharmacol (1995) 0.79
Amonafide as first-line chemotherapy for metastatic breast cancer. Eur J Cancer (1994) 0.79
Tyrosine kinase signaling pathways control the expression of retinoic acid receptor-alpha in SK-BR-3 breast cancer cells. Cancer Lett (1997) 0.79
[Results of the first Austrian multicenter ovarian cancer study: prospective randomized comparison of sequential chemotherapy (adriamycin/cisplatin--vincristine/cyclophosphamide--methotrexate) with 2 standard protocols (adriamycin/cyclophosphamide or adriamycin/cisplatin) in stage III and IV patients]. Geburtshilfe Frauenheilkd (1985) 0.79
Modulation of the immunophenotype of ovarian cancer cells by N,N-dimethylformamide and transforming growth factor-beta 1. J Cell Physiol (1993) 0.78
European School of Oncology. First Euro-American Forum on Lung Cancer Treatment. Eur J Cancer (1994) 0.78
Phase II study of XR 5000, an inhibitor of topoisomerases I and II, in advanced colorectal cancer. Eur J Cancer (2002) 0.78
Regulation of interleukin-8 gene expression by all-trans retinoic acid. Biochem Biophys Res Commun (1995) 0.78
Octreotide combined with goserelin in the therapy of advanced pancreatic cancer--results of a pilot study and review of the literature. J Cancer Res Clin Oncol (1997) 0.77
[Therapeutic and prognostic results of a prospective multicenter ovarian cancer study of FIGO stages I and II]. Geburtshilfe Frauenheilkd (1987) 0.77
Genes related to growth and invasiveness are repressed by sodium butyrate in ovarian carcinoma cells. Br J Cancer (1996) 0.77
Instability of the anticancer agent etoposide under in vitro culture conditions. Cancer Chemother Pharmacol (1991) 0.76
Long-term remission in a patient with erythroleukemia following interferon-alpha treatment. J Biol Response Mod (1989) 0.76
[Abdominal computerized tomography in the after-care of ovarian cancers]. Digitale Bilddiagn (1986) 0.76
Chemoradiotherapy with 5-fluorouracil/leucovorin, surgery and adjuvant chemotherapy for locally advanced rectal cancer. Oncol Lett (2010) 0.75
Pharmacokinetics of 4'-O-tetrahydropyranyladriamycin given on a weekly schedule in patients with advanced breast cancer. Cancer Chemother Pharmacol (1995) 0.75
Interferon-alpha induces complete remission in angioimmunoblastic lymphadenopathy (AILD): late development of aplastic anaemia with cytokine abnormalities. Br J Haematol (1991) 0.75
Standard Operating Procedures for clinical trials of the CESAR Central European Society for Anticancer Drug Research--EWIV. Preface. Onkologie (2003) 0.75
[Hepatic tumors]. Acta Med Austriaca (1983) 0.75
Coupling of mitoxantrone to poly(I).poly(C) reduces absorption after intraperitoneal administration. Chemotherapy (1987) 0.75
Effect of adjuvant chemo- or immunotherapy on the prognosis of colorectal cancer operated for cure. Br J Surg (1985) 0.75
Possible adverse effect of failed adjuvant chemotherapy on the prognosis of women receiving consecutive chemotherapy for recurrent breast cancer. J Cancer Res Clin Oncol (1987) 0.75
[The course of the urea cycle in the liver of the chicken (author's transl)]. Zentralbl Veterinarmed A (1974) 0.75
The role of chemotherapy including ifosfamide for ovarian carcinoma. Austrian Collab. Ovarian Cancer Study Group. Cancer Chemother Pharmacol (1990) 0.75
[Importance of platinum dose intensity in treatment of epithelial ovarian cancer. Austrian Study Group for Therapy of Ovarian Cancer]. Wien Klin Wochenschr (1993) 0.75
[Immunoassay using the hemoglobin pseudoperoxidase activity as indicator]. Z Med Lab Diagn (1982) 0.75
Monitoring the cytotoxic potential of a sequential polychemotherapy (adriamycin/cisplatin-vincristine/cyclophosphamide-high dose methotrexate) in patients with advanced ovarian cancer with the tumor marker CA-125. Cancer Detect Prev (1986) 0.75
[Plasmapheresis in extra-intestinal manifestations of Crohn's disease]. Wien Klin Wochenschr (1984) 0.75
[In vitro chemosensitivity testing with the human tumor stem cell assay (HTSCA) in breast cancer]. Wien Klin Wochenschr (1984) 0.75
[Carboplatin, VP-16 in epithelial ovarian cancer--initial experiences]. Gynakol Rundsch (1988) 0.75
Prediction of toxicity but not of clinical course by determining carboplatin exposure in patients with epithelial ovarian cancer treated with a combination of carboplatin and cisplatin. Int J Oncol (1998) 0.75
[Adjuvant chemotherapy in patients with radical resection of stomach cancer: 5-year results of a prospective randomized study]. Wien Klin Wochenschr (1986) 0.75
[Goserelin--a new form of hormone therapy in ovarian cancer]. Gynakol Rundsch (1990) 0.75
Prevalence of antibodies to hepatitis C virus in patients with hepatocellular carcinoma in Austria. Arch Virol Suppl (1992) 0.75
Assessment of the human tumor cloning assay for urologic malignancies with special emphasis on bladder cancer. Oncology (1986) 0.75
Permanent cure of hydroa vacciniforme after chemotherapy for Hodgkin's disease. Br J Dermatol (1988) 0.75
[High-dose epirubicin in combination with high-dose ifosfamide plus granulocyte colony stimulating factor in patients with advanced platin-pretreated ovarian cancer. Phase I-II study]. Gynakol Geburtshilfliche Rundsch (1993) 0.75
[Differential prognosis of patients with breast cancer with pleuritis carcinomatosa and with pulmonary lymphangiosis carcinomatosa]. Wien Klin Wochenschr (1992) 0.75
Vinorelbine after paclitaxel in breast cancer: cross resistance and cumulative neurotoxicity? Ann Oncol (1994) 0.75
[A model of the blood circulation system with extensive pulsing simulation as basis of monitoring artificial heart]. Med Tekh (1997) 0.75
[Interferon alpha 2C in the treatment of 2 patients with AIDS-associated Kaposi sarcoma]. Wien Klin Wochenschr (1987) 0.75
[Determination of enzymes of the urea cycle, glutaminase and asparaginase in cattle and pigs]. Zentralbl Veterinarmed A (1974) 0.75
[Acute self-poisoning with arsenic and treatment with BAL (author's transl)]. Wien Klin Wochenschr (1978) 0.75
[Mitoxantrone in the primary treatment of metastasizing breast cancer]. Wien Klin Wochenschr (1984) 0.75
Plasmapheresis in the treatment of myasthenia gravis. Wien Klin Wochenschr (1983) 0.75
High dose single-agent paclitaxel in a hemodialysis patient with advanced ovarian cancer: a case report with pharmacokinetic analysis and review of the literature. Int J Gynecol Cancer (2008) 0.75
[Monitoring of cardiac function during doxorubicin therapy in metastasized breast cancer. Measuring systolic time interval]. Dtsch Med Wochenschr (1983) 0.75
Effective salvage therapy with carboplatin/mitomycin C in metastatic breast cancer. Onkologie (2002) 0.75
Report on the XV Congress of the European Society for Medical Oncology (ESMO) Copenhagen, December 2-5, 1990. Wien Klin Wochenschr (1991) 0.75
[Reversible opening of the blood-brain barrier in the chemotherapy of malignant gliomas]. Wien Klin Wochenschr (1987) 0.75
Phase II trial of recombinant interferon alpha-2C in metastatic renal cell carcinoma. J Biol Regul Homeost Agents (1988) 0.75
The effect of adjuvant chemotherapy in gastric carcinoma is dependent on tumor histology: 5-year results of a prospective randomized trial. Recent Results Cancer Res (1988) 0.75
[Quantitative determination of factor VIII antigen with an enzyme immunoassay]. Acta Biol Med Ger (1982) 0.75
Blood brain barrier modification and chemotherapy. Interventional neuroradiology in the treatment of malignant gliomas. Acta Radiol Suppl (1986) 0.75
[Development of an enzyme immunoassay for determination of factor VIII antigens]. Acta Biol Med Ger (1982) 0.75
[Pharmacokinetics and acute signs of cardiac toxicity during doxorubicin therapy]. Wien Klin Wochenschr (1983) 0.75
[5-Fluorouracil (5-FU)/leucovorin in comparison to other current chemotherapy protocols in metastasizing colorectal carcinoma]. Wien Klin Wochenschr (1991) 0.75
Crossed immuno-affinity electrophoresis--a method for analysing the interactions of factor VIII-related antigen with vessel wall proteins. Thromb Res (1982) 0.75